Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in Alzheimer's disease.

R W Hamill1, D M Pilgrim

  • 1Department of Neurology, University of Vermont, Medical Center Hospital of Vermont, Burlington, USA.

Contemporary Internal Medicine
|June 7, 1995
PubMed
Summary

Future drug therapies for this disorder are emerging, focusing on factors like neurotransmitters and apolipoprotein E. Current care emphasizes managing immediate behavioral issues by identifying and resolving their underlying causes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis C virus infection: a risk factor for Parkinson's disease.

Journal of viral hepatitis·2016
Same author

Central regulation of sympathetic ganglia development: heterogeneous response of paravertebral, prevertebral, and terminal ganglia.

Annals of the New York Academy of Sciences·1998
Same author

Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons.

Archives of neurology·1997
Same author

Weight loss in people with Alzheimer's disease: a prospective population based analysis.

BMJ (Clinical research ed.)·1997
Same author

Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons.

Journal of neurochemistry·1996
Same author

Prevalence of parkinsonian signs and associated mortality in a community population of older people.

The New England journal of medicine·1996

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • This disorder is linked to various contributing factors.
  • Neurotransmitters and apolipoprotein E are among the implicated elements.

Purpose of the Study:

  • To explore the factors contributing to this disorder.
  • To inform future therapeutic strategies and current patient management.

Main Methods:

  • Review of current research linking specific factors to the disorder.
  • Analysis of existing patient care approaches.

Main Results:

  • Identification of neurotransmitters and apolipoprotein E as key areas of investigation.
  • Recognition of the need for dual approaches: long-term therapeutic development and immediate behavioral symptom management.

Conclusions:

  • Research into factors like neurotransmitters and apolipoprotein E holds promise for future drug therapies.
  • Effective patient care requires addressing both the root causes and immediate behavioral manifestations of the disorder.

Related Experiment Videos